IBIO News and Press, iBio Inc. From 06/24/25

2025-06-24 14:00:35 ET Capricor Therapeutics Rises 18% on FDA Progress for Duchenne Cell Therapy Capricor Therapeutics, Inc. ( CAPR ) jumped 18.23% to lead the PRISM Emerging Biotech Index after providing a regulatory update on its Biologics License Application (BLA) for...

2025-06-24 07:19:56 ET DENVER, Colo., Jun 24, 2025 ( 247marketnews.com )- Three biotech companies, iBio (NASDAQ:IBIO) , Nektar Therapeutics (NASDAQ:NKTR) , and Immunic (NASDAQ:IMUX) , are stepping into the spotlight this week with pivotal updates. From next-generation obesit...

Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-ac...

Review of promising Myostatin and Activin E antibody data iBio to announce 3 rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator ...

iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body composition Mouse study shows IBI...

Redwire Corporation (RDW) is expected to report $-0.2 for Q1 2025 Organigram Global Inc. (OGI) is expected to report $-0.03 for Q2 2025 Inter & Co. Inc. (INTR) is expected to report $0.12 for Q1 2025 Pervasip Corp (PVSP) is expected to report for quarter end 2025-02-28 Maui La...

iBio Inc. (IBIO) is expected to report $-0.39 for Q3 2025

Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscle Strong synergistic effect on fat...

2025-05-02 08:06:59 ET More on iBio Seeking Alpha’s Quant Rating on iBio Historical earnings data for iBio Financial information for iBio Read the full article on Seeking Alpha For further details see: iBio GAAP EPS of -$0.49 misses by $0.24

SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress. “During the third quarter we were able to broaden our access to investors given our move t...